menu
    • menu
    [{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"NICHD","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Funding","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Implant","sponsorNew":"Dar\u00e9 Bioscience \/ NICHD","highestDevelopmentStatusID":"5","companyTruncated":"Dar\u00e9 Bioscience \/ NICHD"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Implant","sponsorNew":"Dar\u00e9 Bioscience \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Dar\u00e9 Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2024","type":"Funding","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Implant","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Dar\u00e9 Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2024","type":"Funding","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Implant","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Dar\u00e9 Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SN132D","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Spago Nanomedical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spago Nanomedical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Spago Nanomedical \/ Inapplicable"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Merigolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hansoh Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hansoh Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Coagulant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"CT-001","moa":"Factor VII","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Coagulant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Coagulant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Coagulant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coagulant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CT-001","moa":"Factor VII","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Coagulant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Coagulant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Coagulant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coagulant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CT-001","moa":"Factor VII","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Coagulant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Coagulant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Coagulant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antiva Biosciences","sponsor":"Adjuvant Capital","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series D Financing","leadProduct":"ABI-2280","moa":"HPV replication","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Antiva Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antiva Biosciences \/ Adjuvant Capital","highestDevelopmentStatusID":"5","companyTruncated":"Antiva Biosciences \/ Adjuvant Capital"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Hansoh Pharma

                            China arrow
                            German Wound Congress
                            Not Confirmed

                            Hansoh Pharma

                            China arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Merigolix

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hansoh Expands Merigolix use with ART Development Initiation

                            Details : HS-10518 (merigolix) is a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist, which is being investigated for improvement of pregnancy rate per cycle.

                            Product Name : HS-10518

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 20, 2025

                            Lead Product(s) : Merigolix

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Daré Bioscience

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Daré Bioscience

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levonorgestrel

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : IND Enabling

                            Sponsor : NICHD

                            Deal Size : $49.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Dar Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Techn...

                            Details : The funding will be used to advance the development of Daré’s investigational contraceptive DARE-LARC1, an investigational, pre-clinical stage contraceptive implant delivering levonorgestrel, through nonclinical proof of principle studies.

                            Product Name : DARE-LARC1

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            September 21, 2023

                            Lead Product(s) : Levonorgestrel

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : IND Enabling

                            Sponsor : NICHD

                            Deal Size : $49.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Comanche Biopharma

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed

                            Comanche Biopharma

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CBP-4888

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comanche Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for CBP-4888, an siRN...

                            Details : CBP-4888 is a fixed-dose combination of two chemically-synthesized, lipid-conjugated siRNAs duplex oligonucleotides (siRNA-2283 and siRNA-2519) targeting and decreasing the production of soluble fms-like tyrosine kinase-1 in the placenta, as a treament f...

                            Product Name : CBP-4888

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            March 30, 2023

                            Lead Product(s) : CBP-4888

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Coagulant Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Coagulant Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CT-001

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Coagulant Therapeutics Announces Publication in Blood Advances Describing Novel Nanobody Library to Activated ...

                            Details : CT-001 is an engineered FVIIa that is designed to address the limitations of the recombinant FVIIa, approved for use in Hemophilia A and B patients with inhibitors, congenital FVII deficiency and Glanzmann’s thrombasthenia with refractoriness to platel...

                            Product Name : CT-001

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            February 27, 2023

                            Lead Product(s) : CT-001

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Coagulant Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Coagulant Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CT-001

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Coagulant Therapeutics Presents Data for Severe Postpartum Hemorrhage Clinical Candidate, CT-001, at Internati...

                            Details : CT-001 is an engineered version of clotting factor FVIIa designed to address safety and efficacy limitations of recombinant FVIIa is approved for use in Hemophilia A and B patients with inhibitors.

                            Product Name : CT-001

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 07, 2022

                            Lead Product(s) : CT-001

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Coagulant Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Coagulant Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CT-001

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Coagulant Therapeutics Announces Publication of In Vivo Data Demonstrating Safety and Efficacy of CT-001 for t...

                            Details : The in vivo studies compared the safety and efficacy of CT-001 versus recombinant FVIIa in multiple mouse models. The studies confirmed that desialylation of the molecule increased the speed by which it cleared from the body.

                            Product Name : CT-001

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            July 07, 2022

                            Lead Product(s) : CT-001

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Spago Nanomedical

                            Sweden arrow
                            German Wound Congress
                            Not Confirmed

                            Spago Nanomedical

                            Sweden arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SN132D

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Spago Nanomedical Initiates Clinical Trial with SpagoPix in Endometriosis and Concludes SPAGOPIX-01

                            Details : The study will evaluate the safety and MRI enhancing properties of SN132D in participants with suspected endometriosis. Comparisons will be made to transvaginal ultrasound and conventional MRI in order to consider the diagnostic potential of SN132D in en...

                            Product Name : SN132D

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 12, 2022

                            Lead Product(s) : SN132D

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Tauriga Sciences

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Tauriga Sciences

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tauriga Sciences Inc. Formally Submits its Clinical Study Protocol to the Institutional Review Board

                            Details : The purpose of this clinical study is to examine the effects of different cannabidiol doses on reducing the frequency and severity of nausea in otherwise healthy pregnant women with excessive first trimester emesis and the diagnosis of hyperemesis gravid...

                            Product Name : Tauri-Gum

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            December 17, 2021

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Antiva Biosciences

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Antiva Biosciences

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABI-2280

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : IND Enabling

                            Sponsor : Adjuvant Capital

                            Deal Size : $31.0 million

                            Deal Type : Series D Financing

                            DEALS_DEV arrow-down

                            Antiva Biosciences Closes $31 Million Series D Equity Financing

                            Details : Proceeds from the financing will support the development of the company’s lead development candidate, ABI-2280, including the near-term advancement of the compound into Phase 1 and 2a clinical trials as a potential treatment for high-grade cervical int...

                            Product Name : ABI-2280

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 11, 2021

                            Lead Product(s) : ABI-2280

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : IND Enabling

                            Sponsor : Adjuvant Capital

                            Deal Size : $31.0 million

                            Deal Type : Series D Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth